Is CAH or IDXX cheaper?

On trailing earnings, CAH is cheaper: CAH trades at a 34.23 P/E and IDXX at 41.36.

Which has grown faster, CAH or IDXX?

Over the past five years, CAH grew revenue faster — CAH at a 9.86% CAGR versus IDXX at 9.24%.

Does CAH or IDXX pay a bigger dividend?

CAH pays a dividend (0.91% yield) while IDXX does not currently pay one.

Is CAH or IDXX more profitable?

IDXX runs the higher net margin — CAH at 0.62% versus IDXX at 24.63%.

Which has been the better investment, CAH or IDXX?

Over the past 10-year, IDXX delivered the higher annualized total return — CAH at 14.21% versus IDXX at 20.22%. Past performance doesn't predict future results.

Cardinal Health, Inc. (CAH) vs IDEXX Laboratories, Inc. (IDXX)

CAH leads on 9 of 15 compared metrics.

A side-by-side comparison of Cardinal Health, Inc. and IDEXX Laboratories, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 15, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

CAH

Cardinal Health, Inc.

$52.43B

$223.85Healthcare

IDXX

IDEXX Laboratories, Inc.

$44.24B

$560.88Healthcare

Total return — CAH vs IDXX

growth of $100 · last 30y

CAH +910.6%IDXX +10042.5%IDXX compounded faster

Log scale — wide-divergence pair

CAH IDXX

CAH vs IDXX: by the numbers

•CAH is the larger company ($52.43B vs $44.24B market cap).
•CAH trades at the lower earnings multiple (34.23 vs 41.36 P/E).
•IDXX converts more revenue to profit (24.63% vs 0.62% net margin).
•CAH grew revenue faster over the past five years (9.86% vs 9.24% CAGR).
•CAH pays a dividend (0.91% yield) while IDXX does not currently pay one.

Which is better, CAH or IDXX?

Metric tally: CAH 9 · IDXX 6

It depends on what you're optimizing for:

ValueCAH(lower P/E)

GrowthCAH(faster 5Y revenue CAGR)

QualityIDXX(higher ROIC)

Metrics side by side

Valuation

Metric	CAH	IDXX
P/E ratio	34.23●	41.36
Forward P/E	18.64●	33.85
P/S ratio	0.21●	10.18
P/B ratio	—	29.08
PEG ratio	0.30●	2.30
EV / EBITDA	19.10●	29.61
FCF yield	8.31%●	2.39%

Profitability

Metric	CAH	IDXX
Gross margin	3.68%	62.05%●
Operating margin	0.92%	31.63%●
Net margin	0.62%	24.63%●
ROE	-56.13%	70.38%●
ROIC	11.37%	40.27%●

Dividends

Metric	CAH	IDXX
Dividend yield	0.91%	—
Payout ratio	31.52%	—

Growth (annualized)

Metric	CAH	IDXX
Revenue CAGR (5Y)	9.86%●	9.24%
EPS CAGR (5Y)	6.11%	14.07%●
FCF CAGR (5Y)	22.47%●	10.13%
Total return CAGR (5Y)	33.46%●	-0.82%

Frequently asked

Which is better, CAH or IDXX?: It depends on your goal. value: CAH (lower P/E); growth: CAH (faster 5Y revenue CAGR); quality: IDXX (higher ROIC). Across all compared metrics, CAH leads 9 to 6.
Is CAH or IDXX cheaper?: On trailing earnings, CAH is cheaper: CAH trades at a 34.23 P/E and IDXX at 41.36.
Which has grown faster, CAH or IDXX?: Over the past five years, CAH grew revenue faster — CAH at a 9.86% CAGR versus IDXX at 9.24%.
Does CAH or IDXX pay a bigger dividend?: CAH pays a dividend (0.91% yield) while IDXX does not currently pay one.
Is CAH or IDXX more profitable?: IDXX runs the higher net margin — CAH at 0.62% versus IDXX at 24.63%.
Which has been the better investment, CAH or IDXX?: Over the past 10-year, IDXX delivered the higher annualized total return — CAH at 14.21% versus IDXX at 20.22%. Past performance doesn't predict future results.

Go deeper

Full CAH analysis Full IDXX analysis Interactive comparison tool

Dig into the metrics

Cardinal Health P/E ratio IDEXX Laboratories P/E ratio Cardinal Health dividend yield IDEXX Laboratories dividend yield Cardinal Health ROE IDEXX Laboratories ROE Cardinal Health operating margin IDEXX Laboratories operating margin Cardinal Health revenue growth IDEXX Laboratories revenue growth Cardinal Health free cash flow IDEXX Laboratories free cash flow

Cardinal Health & IDEXX Laboratories appear in these rankings

Dividend Aristocrats Highest ROE Stocks Highest ROIC Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 15, 2026.